Main clinical and biochemical data at the time of screening
| Age at screening (y) | 53 (36-87), n (%) |
| BMI (kg/m2) | 24.6 (17.3-40.6) |
| Hemophilia | |
| A | 108 (91) |
| Mild/moderate/severe | 19/13/76 (16/11/64) |
| B | 11 (9) |
| Mild/moderate/severe | 1/2/8 (1/2/7) |
| Years from eradication | 5 (1-33) |
| Age at eradication or datable clearance | 46 (13-81) |
| Alcohol (≥14 AUs per week) | 14 (12) |
| NAFLD | 46 (39) |
| Patients with alteration of transaminases/cholestasis | 17(14)/26(22) |
| Elevated AST (>33 U/L)/ALT (>41 U/L) | 13 (11)/8 (7) |
| Elevated GGT (>36 U/L)/elevated ALP (>104 U/L)∗ | 22 (19)/9 (8) |
| AST (U/L)/ALT (U/L) | 25 (15-93)/24 (9-80) |
| GGT (U/L)/ALP (U/L) | 20 (6-122) |
| Cholesterol (mg/dL) | 178 (89-253) |
| HDL (mg/dL)/LDL (mg/dL) | 47 (24-85)/101 (47-180) |
| Total bilirubin (mg/dL) | 0.6 (0.2-3.6) |
| Cholinesterase (U/L) | 7880 (3563-12232) |
| Total proteins (g/dL)/albumin (g/dL) | 7.3 (6.3-8.10)/4.6 (3.5-5.5) |
| Alphafetoprotein (ng/mL) | 2.3 (0.1-61.9) |
| Hemoglobin (g/dL) | 14.1 (10-19.6) |
| White blood cells (units × 103/μL) | 5.79 (2.33-11.65) |
| Neutrophils (%)/lymphocytes (%) | 57 (22-83) |
| Platelets (units× 103/μL) | 215 (67-442) |
| Patients with platelets ranging from 100-150×103/μL | 7 (6) |
| Patients with platelets <1× 103/μL | 5 (4) |
| Triglycerides (mg/dL) | 96 (40-513) |
| Glycemia (mg/dL) | 89 (67-213) |
| Creatinine (mg/dL) | 0.96 (0.59-1.71) |
| Na (mmol/L) | 141 (123-146) |
| Liver stiffness (KPa)† | 5.5 (2.3-45) |
| APRI score/ FIB-4 score | 0.35 (0.16-1.57) / 1.39 (0.43-7.02) |
| Ultrasound data‡ | |
| Liver Steatosis | 51 (44) |
| Irregular or nodular liver surface | 23 (20) |
| Liver caudate lobe hypertrophy | 8 (7) |
| Splenomegaly | 32 (27) |
| Portal trunk dilated | 9 (8) |
| Focal liver lesions | 12 (10) |
| Age at screening (y) | 53 (36-87), n (%) |
| BMI (kg/m2) | 24.6 (17.3-40.6) |
| Hemophilia | |
| A | 108 (91) |
| Mild/moderate/severe | 19/13/76 (16/11/64) |
| B | 11 (9) |
| Mild/moderate/severe | 1/2/8 (1/2/7) |
| Years from eradication | 5 (1-33) |
| Age at eradication or datable clearance | 46 (13-81) |
| Alcohol (≥14 AUs per week) | 14 (12) |
| NAFLD | 46 (39) |
| Patients with alteration of transaminases/cholestasis | 17(14)/26(22) |
| Elevated AST (>33 U/L)/ALT (>41 U/L) | 13 (11)/8 (7) |
| Elevated GGT (>36 U/L)/elevated ALP (>104 U/L)∗ | 22 (19)/9 (8) |
| AST (U/L)/ALT (U/L) | 25 (15-93)/24 (9-80) |
| GGT (U/L)/ALP (U/L) | 20 (6-122) |
| Cholesterol (mg/dL) | 178 (89-253) |
| HDL (mg/dL)/LDL (mg/dL) | 47 (24-85)/101 (47-180) |
| Total bilirubin (mg/dL) | 0.6 (0.2-3.6) |
| Cholinesterase (U/L) | 7880 (3563-12232) |
| Total proteins (g/dL)/albumin (g/dL) | 7.3 (6.3-8.10)/4.6 (3.5-5.5) |
| Alphafetoprotein (ng/mL) | 2.3 (0.1-61.9) |
| Hemoglobin (g/dL) | 14.1 (10-19.6) |
| White blood cells (units × 103/μL) | 5.79 (2.33-11.65) |
| Neutrophils (%)/lymphocytes (%) | 57 (22-83) |
| Platelets (units× 103/μL) | 215 (67-442) |
| Patients with platelets ranging from 100-150×103/μL | 7 (6) |
| Patients with platelets <1× 103/μL | 5 (4) |
| Triglycerides (mg/dL) | 96 (40-513) |
| Glycemia (mg/dL) | 89 (67-213) |
| Creatinine (mg/dL) | 0.96 (0.59-1.71) |
| Na (mmol/L) | 141 (123-146) |
| Liver stiffness (KPa)† | 5.5 (2.3-45) |
| APRI score/ FIB-4 score | 0.35 (0.16-1.57) / 1.39 (0.43-7.02) |
| Ultrasound data‡ | |
| Liver Steatosis | 51 (44) |
| Irregular or nodular liver surface | 23 (20) |
| Liver caudate lobe hypertrophy | 8 (7) |
| Splenomegaly | 32 (27) |
| Portal trunk dilated | 9 (8) |
| Focal liver lesions | 12 (10) |
Continuous variables are presented as medians and minimum-maximum ranges, and categorical variables are presented as numbers and proportions.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BMI, body mass index; GGT, gamma-glutamil transferase; HDL, high density lipoprotein; LDL, low density lipoporotein.
Data available on 97 patients.
Data available on 90 patients.
Data available on 117 patients.